MDA Grantees Prove Gene Therapy Grows Muscle Strength & Size In Primates
Longtime MDA grantee Jerry Mendell, a neurologist at Nationwide Children's Hospital in Columbus, Ohio, and Brian Kaspar, a research scientist at that institution who has also received MDA funding, led the study team, which published its findings Nov. 11, 2009, in Science Translational Medicine. Although this treatment strategy will not address the underlying problems in muscle diseases, it may result in a strengthening of remaining muscle.
"Laser sharp is this pioneering gene therapy work with primates," says R. Rodney Howell, M.D., Chairman of the MDA Board of Directors. "It's exciting to see profound improvement in muscle size and strength with no adverse effects on any organs or systems including the heart. Improvement in treated thigh muscle is noteworthy because the large muscle is so important when people sit, rise from sitting and for mobility."
MDA, which has invested more than $10 million funding elegant research involving Dr. Mendell during the past 20 years, has asked Mendell to submit a grant application for a phase-one clinical trial as soon as possible.
"This study represents real proof-of-concept that it is possible to improve muscle strength with a gene delivery strategy. The strategy is showing true promise." adds Sharon Hesterlee, Ph.D., Senior Vice President for MDA Venture Philanthropy.
"Over the years, Jerry Mendell has received more direct funding from MDA than any other investigator," she explains, "because he keeps finding innovative ways to help the patients he sees every week in the MDA clinic."
Mendell is codirector of the MDA neuromuscular disease clinic at Nationwide, where he also heads one of five elite centers of excellence in Duchenne muscular dystrophy comprising the MDA DMD Clinical Research Network.
About today's findings
Follistatin is a natural body protein that promotes muscle growth and strength by interfering with the actions of another natural protein, known as myostatin.
Myostatin blocking, a treatment strategy that MDA has been pursuing for several years, is a promising approach to maintain muscle tissue in the face of degenerative disease.
Administering genes for the follistatin protein is one of several ways to inhibit myostatin, a strategy that has the potential to help people with all forms of muscular dystrophy and possibly many other types of neuromuscular diseases.
The monkeys used in this study did not have a muscle disease, but the researchers say they believe follistatin genes would probably help people who do, because such genes have previously helped mice with a disease resembling Duchenne muscular dystrophy, the most common childhood form of MD.
MDA is the nonprofit health agency dedicated to curing muscular dystrophy, amyotrophic lateral sclerosis (ALS) and related diseases by funding worldwide research. The Association also provides comprehensive health care and support services, advocacy and education.
Source: Muscular Dystrophy Association (MDA)
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:
Association, Muscular Dystrophy. "MDA Grantees Prove Gene Therapy Grows Muscle Strength & Size In Primates." Medical News Today. MediLexicon, Intl., 12 Nov. 2009. Web.
20 Jan. 2017. <http://www.medicalnewstoday.com/releases/170680.php>
Association, M. (2009, November 12). "MDA Grantees Prove Gene Therapy Grows Muscle Strength & Size In Primates." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.